GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
i had a feeling XAIR was gonna take-off. great call! if anyone's interested i think i've found a small biotech with potential. phase 3 etc., looking for fda approval next year. yes, i found it on reddit. is it another pump and dump? maybe in the short-term but i really believe the tech is simple enough that it will get fda approval at some point in the future - no idea when. i leave it up to Stoney if he wants the ticker in the Phantasma.
Let it rip Unconventional maybe I know the Co.
I think there may be a backdoor Covid pay to this XAIR. I have read on some of these weird sites that one of the crazy self-treatments for Covid is Nitric Oxide...
So I searched and I did find an important peer reviewed case---
It is with this backdrop that, in this issue of the Journal, Zamanian and colleagues (pp.130–132) present an interesting and compelling case of a patient with pulmonary arterial hypertension (PAH) who was treated remotely in an ambulatory setting with inhaled nitric oxide (iNO) (5). This patient with well-controlled vasoreactive PAH lived in a remote area more than 300 miles away from their center and experienced symptoms of worsening breathlessness after being diagnosed with COVID-19. Considering her concerns about traveling the long distance to their center to receive care, and with recognition of her prior confirmed responsiveness to iNO, they established a plan to support her with an ambulatory iNO system while monitoring her symptoms, vital signs, and functional capacity remotely. The patient had rapid and sustained improvement in her 6-minute-walk distance, as assessed by her caregiver, and symptom score, and she recovered over several days without having to engage emergency department or hospital care.
This case report raises many questions. How might iNO have benefited this patient? Would we expect the benefit to be unique to iNO, or could other therapies that increase signaling along the NO axis also be helpful, such as NO donors, NO precursors, or phosphodiesterase 5 inhibitors? Can NO be safely administered to a patient in their own home, potentially helping to unburden overwhelmed healthcare systems?
NO is a free radial gas that functions as an important signaling molecule in human physiology. Its canonical receptor, guanylate cyclase, is highly expressed vascular smooth muscle cells, where it becomes activated once NO binds to its heme moiety, significantly increasing its enzymatic conversion of guanosine-5′-triphosphate to cyclic guanosine monophosphate, which subsequently promotes vasorelaxation. As a gas, it has unique pharmacological properties including its delivery into well-ventilated lung units where it promotes local vasodilatation. When NO enters the blood stream, it rapidly reacts with intraerythrocytic Hb, thus inactivating the NO, resulting in an extremely short half-life, which limits its systemic effects. By preferentially vasodilating pulmonary arterioles in well-ventilated lung units, it decreases the relative blood flow to poorly ventilated lung units and enhancesV./Q.matching, increasing oxygenation (6). NO also induces mild bronchodilation, and inhibits neutrophil-mediated oxidative burst (6). These properties have been well known for decades and have led to U.S. Food and Drug Administration approval for the treatment of persistent pulmonary hypertension of the newborn, as well as various trials of iNO for patients with myriad conditions including ARDS, right ventricular failure after cardiac surgery, acute pulmonary embolism, and more recently pulmonary fibrosis in patients requiring long-term oxygen therapy (6–10). In patients with SARS, iNO was associated with improvements in oxygenation in a severity-matched observational cohort (11). Both endogenous and exogenous NO were shown to inhibit SARS-CoV viral replication (12). While iNO has not been shown to reduce the time on mechanical ventilation or mortality in adults with ARDS, iNO does significantly improve oxygenation in ARDS patients and leads to reduction in pulmonary vascular resistance (6) (Figure 1). These therapeutic responses suggest that iNO could be used early in the course of COVID-19 infection to reduce the need for invasive mechanical ventilation. <--- HEY ROBIN HOOD!!!!
I think there may be a backdoor Covid pay to this XAIR. I have read on some of these weird sites that one of the crazy self-treatments for Covid is Nitric Oxide...
So I searched and I did find an important peer reviewed case---
It is with this backdrop that, in this issue of the Journal, Zamanian and colleagues (pp.130–132) present an interesting and compelling case of a patient with pulmonary arterial hypertension (PAH) who was treated remotely in an ambulatory setting with inhaled nitric oxide (iNO) (5). This patient with well-controlled vasoreactive PAH lived in a remote area more than 300 miles away from their center and experienced symptoms of worsening breathlessness after being diagnosed with COVID-19. Considering her concerns about traveling the long distance to their center to receive care, and with recognition of her prior confirmed responsiveness to iNO, they established a plan to support her with an ambulatory iNO system while monitoring her symptoms, vital signs, and functional capacity remotely. The patient had rapid and sustained improvement in her 6-minute-walk distance, as assessed by her caregiver, and symptom score, and she recovered over several days without having to engage emergency department or hospital care.
This case report raises many questions. How might iNO have benefited this patient? Would we expect the benefit to be unique to iNO, or could other therapies that increase signaling along the NO axis also be helpful, such as NO donors, NO precursors, or phosphodiesterase 5 inhibitors? Can NO be safely administered to a patient in their own home, potentially helping to unburden overwhelmed healthcare systems?
NO is a free radial gas that functions as an important signaling molecule in human physiology. Its canonical receptor, guanylate cyclase, is highly expressed vascular smooth muscle cells, where it becomes activated once NO binds to its heme moiety, significantly increasing its enzymatic conversion of guanosine-5′-triphosphate to cyclic guanosine monophosphate, which subsequently promotes vasorelaxation. As a gas, it has unique pharmacological properties including its delivery into well-ventilated lung units where it promotes local vasodilatation. When NO enters the blood stream, it rapidly reacts with intraerythrocytic Hb, thus inactivating the NO, resulting in an extremely short half-life, which limits its systemic effects. By preferentially vasodilating pulmonary arterioles in well-ventilated lung units, it decreases the relative blood flow to poorly ventilated lung units and enhancesV./Q.matching, increasing oxygenation (6). NO also induces mild bronchodilation, and inhibits neutrophil-mediated oxidative burst (6). These properties have been well known for decades and have led to U.S. Food and Drug Administration approval for the treatment of persistent pulmonary hypertension of the newborn, as well as various trials of iNO for patients with myriad conditions including ARDS, right ventricular failure after cardiac surgery, acute pulmonary embolism, and more recently pulmonary fibrosis in patients requiring long-term oxygen therapy (6–10). In patients with SARS, iNO was associated with improvements in oxygenation in a severity-matched observational cohort (11). Both endogenous and exogenous NO were shown to inhibit SARS-CoV viral replication (12). While iNO has not been shown to reduce the time on mechanical ventilation or mortality in adults with ARDS, iNO does significantly improve oxygenation in ARDS patients and leads to reduction in pulmonary vascular resistance (6) (Figure 1). These therapeutic responses suggest that iNO could be used early in the course of COVID-19 infection to reduce the need for invasive mechanical ventilation. <--- HEY ROBIN HOOD!!!!
<<<<<<GBA'S ESG PORTFOLIO>>>>>>> I THINK AT THIS POINT WE COULD MAKE ONE!
Environmental, social and corporate governance
Description
Description
Environmental, Social, and Corporate Governance data refers to metrics related to intangible assets within the enterprise, a form of corporate social credit score. Research shows that intangible assets comprise an increasing percentage of future enterprise value.
Bloom Energy price target raised to $34 from $29 at JPMorgan 08:28
BE
JPMorgan analyst Mark Strouse raised the firm's price target on Bloom Energy to $34 from $29 and keeps an Overweight rating on the shares. Heading into the Q3 prints, alternative energy investor focus will likely remain on supply chain disruptions near-term, potentially creating volatility in the stocks that could present attractive buying opportunities, Strouse tells investors in a research note. The analyst says that with an average trading multiple below the one-year average, he remains positive on the stocks heading into the results.
ShowRelated Items >>
Over a week ago
Bloom Energy assumed with an Outperform at Credit Suisse 07/13
BE
Credit Suisse analyst Maheep Mandloi assumed coverage of Bloom Energy with an Outperform rating and $35 price target.
TODAY) Bloom Energy, Heliogen to produce green hydrogen using solar power and water »
Environmental, social and corporate governance
Description
Description
Environmental, Social, and Corporate Governance data refers to metrics related to intangible assets within the enterprise, a form of corporate social credit score. Research shows that intangible assets comprise an increasing percentage of future enterprise value.
Bloom Energy price target raised to $34 from $29 at JPMorgan 08:28
BE
JPMorgan analyst Mark Strouse raised the firm's price target on Bloom Energy to $34 from $29 and keeps an Overweight rating on the shares. Heading into the Q3 prints, alternative energy investor focus will likely remain on supply chain disruptions near-term, potentially creating volatility in the stocks that could present attractive buying opportunities, Strouse tells investors in a research note. The analyst says that with an average trading multiple below the one-year average, he remains positive on the stocks heading into the results.
ShowRelated Items >>
Over a week ago
Bloom Energy assumed with an Outperform at Credit Suisse 07/13
BE
Credit Suisse analyst Maheep Mandloi assumed coverage of Bloom Energy with an Outperform rating and $35 price target.
TODAY) Bloom Energy, Heliogen to produce green hydrogen using solar power and water »
Flux Power announces order backlog of $13.7M 08:20 FLUX
NRx Pharmaceuticals announces commercial formulation of Zyesami 08:20 NRXP
Energy Recovery gets $6M in contract awards for PX Pressure Exchanger 08:15 ERII
Electric Last Mile files patent application for EV crash protection system 08:07 ELMS Electric Last Mile Solutions announcedthat it has filed a provisional patent with the United States Patent and Trademark Office related to the development of its EV crash protection system to improve vehicle and occupant safety and battery stability in the event of a collision. The design encompassed in ELMS' provisional patent application allows for the hollow channel bumper, crash boxes, tubular supports and ring assembly to crumple in stages upon frontal impact to absorb and redirect the energy to protect the occupant as well as the high voltage battery. ELMS expects to hold its next round of crash tests in August and intends to utilize the energy-absorbing front body vehicle assembly design in the Urban Delivery, which the Company intends to launch later this year. The ELMS' Urban Delivery is expected to be the first Class 1 commercial electric vehicle available in the U.S. market and will be produced at the Company's 675,000 square foot plant in Mishawaka, Indiana.
NRx Pharmaceuticals announces commercial formulation of Zyesami 08:20 NRXP
Energy Recovery gets $6M in contract awards for PX Pressure Exchanger 08:15 ERII
Electric Last Mile files patent application for EV crash protection system 08:07 ELMS Electric Last Mile Solutions announcedthat it has filed a provisional patent with the United States Patent and Trademark Office related to the development of its EV crash protection system to improve vehicle and occupant safety and battery stability in the event of a collision. The design encompassed in ELMS' provisional patent application allows for the hollow channel bumper, crash boxes, tubular supports and ring assembly to crumple in stages upon frontal impact to absorb and redirect the energy to protect the occupant as well as the high voltage battery. ELMS expects to hold its next round of crash tests in August and intends to utilize the energy-absorbing front body vehicle assembly design in the Urban Delivery, which the Company intends to launch later this year. The ELMS' Urban Delivery is expected to be the first Class 1 commercial electric vehicle available in the U.S. market and will be produced at the Company's 675,000 square foot plant in Mishawaka, Indiana.
Veritone trading resumes 07:35 VERI -
Veritone acquires PandoLogic in 'immediately accretive' deal for $150M 07:17 VERI Veritone announced it signed a definitive agreement to acquire PandoLogic. Total consideration of $150M on a cash and debt free basis, payable in Veritone cash and stock, with performance earnouts through fiscal 2022. This values the transaction at approximately three times PandoLogic's expected 2021 GAAP revenues. The acquisition is expected to be immediately accretive, with PandoLogic generating over $50Mn in SaaS and related GAAP revenues and over $25M of EBITDA on a pro forma 2021 basis. PandoLogic utilizes AI to accelerate the time and improve the efficiency in the process for employers hiring at scale for both mass market and difficult-to-source candidates. PandoLogic's fully autonomous recruiting platform helps employers source talent faster and more efficiently with predictive algorithms, machine learning and AI. ..Total consideration for the acquisition of PandoLogic is $150M, consisting of upfront payments of $50M cash and $35M in Veritone stock. The remaining 43%, or $65 million in cash and stock, is payable based on earnouts tied to financial performance in fiscal 2021 and 2022. Under the terms of the agreement, Veritone will issue stock consideration valued up to $56.7 million, or 2.8 million shares of Veritone common stock, which are subject to certain trading and registration restrictions. The transaction, subject to customary domestic and Israeli closing conditions, is expected to close late in the third quarter of 2021, with the cash consideration being paid from Veritone's existing reserves. PandoLogic will become a wholly owned subsidiary of Veritone, operating in Israel. Management plans to update Veritone's guidance on August 3 when it releases its second quarter 2021 results.
Veritone acquires PandoLogic in 'immediately accretive' deal for $150M 07:17 VERI Veritone announced it signed a definitive agreement to acquire PandoLogic. Total consideration of $150M on a cash and debt free basis, payable in Veritone cash and stock, with performance earnouts through fiscal 2022. This values the transaction at approximately three times PandoLogic's expected 2021 GAAP revenues. The acquisition is expected to be immediately accretive, with PandoLogic generating over $50Mn in SaaS and related GAAP revenues and over $25M of EBITDA on a pro forma 2021 basis. PandoLogic utilizes AI to accelerate the time and improve the efficiency in the process for employers hiring at scale for both mass market and difficult-to-source candidates. PandoLogic's fully autonomous recruiting platform helps employers source talent faster and more efficiently with predictive algorithms, machine learning and AI. ..Total consideration for the acquisition of PandoLogic is $150M, consisting of upfront payments of $50M cash and $35M in Veritone stock. The remaining 43%, or $65 million in cash and stock, is payable based on earnouts tied to financial performance in fiscal 2021 and 2022. Under the terms of the agreement, Veritone will issue stock consideration valued up to $56.7 million, or 2.8 million shares of Veritone common stock, which are subject to certain trading and registration restrictions. The transaction, subject to customary domestic and Israeli closing conditions, is expected to close late in the third quarter of 2021, with the cash consideration being paid from Veritone's existing reserves. PandoLogic will become a wholly owned subsidiary of Veritone, operating in Israel. Management plans to update Veritone's guidance on August 3 when it releases its second quarter 2021 results.
On24 elevated to bullish Fresh Pick at Baird 07:05 ONTF
BofA starts R1 RCM at Buy, sees 32% upside potential 07:02 RCM
Bally's Interactive, Sportradar announce five-year U.S. sports betting deal 08:08 BALY
Fluor price target lowered
to $20 from $23 at Citi 06:17 FLR Citi analyst Andrew Kaplowitz lowered the firm's price target on Fluor to $20 from $23 and keeps a Neutral rating on the shares.
Missfresh initiated with a Buy at Needham 06:14 MF Needham analyst Vincent Yu initiated coverage of Missfresh with a Buy rating and $12 price target. The company is well positioned in the growing distributed mini warehouse retail market, the analyst tells investors in a research note. Yu adds that Missfresh is resetting its user acquisition initiatives this year, which should drive accelerated GMV growth.
Missfresh initiated with a Buy at China Renaissance 05:55 MF China Renaissance analyst Charlie Chen initiated coverage of Missfresh with a Buy rating and $17.59 price target. China's distributed mini warehouse market is forecast to "take off" from RMB 34B in 2020 to RMB 307B in 2025, driven by technology development and consumer behavior changes, Chen tells investors in a research note. The analyst says Missfresh held 28% market share in 2020 and is expected to achieve "high growth" driven by planned expansion from 622 DMVs in 2020 to 2,600 in 2025.
Cathie Wood's ARK Investment bought 604K shares of DraftKings yesterday 20:30 DKNG
BofA starts R1 RCM at Buy, sees 32% upside potential 07:02 RCM
Bally's Interactive, Sportradar announce five-year U.S. sports betting deal 08:08 BALY
Fluor price target lowered
to $20 from $23 at Citi 06:17 FLR Citi analyst Andrew Kaplowitz lowered the firm's price target on Fluor to $20 from $23 and keeps a Neutral rating on the shares.Missfresh initiated with a Buy at Needham 06:14 MF Needham analyst Vincent Yu initiated coverage of Missfresh with a Buy rating and $12 price target. The company is well positioned in the growing distributed mini warehouse retail market, the analyst tells investors in a research note. Yu adds that Missfresh is resetting its user acquisition initiatives this year, which should drive accelerated GMV growth.
Missfresh initiated with a Buy at China Renaissance 05:55 MF China Renaissance analyst Charlie Chen initiated coverage of Missfresh with a Buy rating and $17.59 price target. China's distributed mini warehouse market is forecast to "take off" from RMB 34B in 2020 to RMB 307B in 2025, driven by technology development and consumer behavior changes, Chen tells investors in a research note. The analyst says Missfresh held 28% market share in 2020 and is expected to achieve "high growth" driven by planned expansion from 622 DMVs in 2020 to 2,600 in 2025.
Cathie Wood's ARK Investment bought 604K shares of DraftKings yesterday 20:30 DKNG
That Bally's news highlights a company Ack may want to SPAC. I'm very surprised these guys have not been SPAC'd...